Signature of working arrangement between EMCDDA and EMA

On 7 December, Mr Goosdeel travels to London to sign the updated EMCDDA–EMA working arrangement with EMA Director Guido Rasi. The former arrangement, which enabled the bilateral sharing of information through the pharmacovigilance system, largely on NPS, has now been extended to include the abuse of substances intended for medicinal use in humans or veterinary products. This reflects the dynamics of the European drug market and the adulteration of existing drugs with medicinal products.

These new arrangements will align the agencies’ working relationships with the new legislation as well as with the on-going observed changes in the European drug situation. They also enable better preparedness for potential future developments in the increasingly complex and fast-moving world of drug production and marketing facing European citizens.